Polymyositis Market Size in the 7MM was ~USD 114 million in 2023 and It is expected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Discover Key Insights into the Polymyositis Market with DelveInsight's In-Depth Report @ Polymyositis Market Size- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Polymyositis Market Report
• In October 2025, Cabaletta Bio initiated a study to assess the safety and efficacy of its investigational cell therapy, CABA-201, in patients with Dermatomyositis (DM), Anti-Synthetase Syndrome (ASyS), Immune-Mediated Necrotizing Myopathy (IMNM), or Juvenile Idiopathic Inflammatory Myopathy (JIIM) who have active disease. The trial will evaluate a single dose of CABA-201 administered in combination with cyclophosphamide (CY) and fludarabine (FLU).
• In October 2025, Novartis Pharmaceuticals launched a Phase II clinical study to compare the efficacy and safety of rapcabtagene autoleucel against a standard comparator in patients suffering from severe refractory idiopathic inflammatory myopathies (IIM).
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Polymyositis in the 7MM were nearly 80 thousand in 2023.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Polymyositis with ~9 thousand cases, followed by France, which had diagnosed prevalent population of ~7 thousand in 2023. On the other hand, Spain had the lowest prevalent population (3 thousand cases).
• Japan had nearly 12 thousand total diagnosed prevalent cases of Polymyositis in 2023, accounting for approximately 16% in 7MM.
• The DelveInsight analysis indicates that in Japan, females were more affected than males, with approximately 9 thousand female cases and 3 thousand male cases in 2023.
• The Polymyositis Companies such as Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
• Promising Polymyositis Therapies such as Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.

Stay ahead in the Polymyositis Therapeutics Market with DelveInsight's Strategic Report @ Polymyositis Market Outlook- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polymyositis Epidemiology Segmentation in the 7MM
• Total Polymyositis Diagnosed Prevalent Cases
• Polymyositis Gender-specific Diagnosed Prevalent Cases
• Polymyositis Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Prevalence- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polymyositis Emerging Drugs
• SAPHNELO (Anifrolumab): AstraZeneca
SAPHNELO (anifrolumab) is a first-in-class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta, and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity.

• Dazukibart (PF-06823859): Pfizer
The drug dazukibart (PF-06823859) is being developed to treat moderate to severe dermatomyositis and Polymyositis by Pfizer along with other indications like systemic lupus erythematosus, subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE). Neutralizing antibodies against humanized immunoglobulin and a new biological entity (NBE) make up the therapeutic candidate. It works by specifically targeting interferon beta 1 (IFNB1) and is injected intravenously and subcutaneously.

Polymyositis Market Outlook
Polymyositis is an inflammatory muscle disease that requires a multifaceted approach to treatment, primarily focusing on reducing inflammation, managing symptoms, and preventing long-term complications. The mainstay of treatment is corticosteroids, such as prednisone, which are often administered as the first line of therapy due to their potent anti-inflammatory effects. These steroids are typically prescribed in high doses initially and gradually tapered based on the patient's response. For patients who do not respond adequately to corticosteroids or who experience significant side effects, immunosuppressive agents such as methotrexate or azathioprine are commonly used. These medications help to modulate the immune system and can be used as steroid-sparing agents to reduce the dependency on corticosteroids.

Get In-Depth Knowledge on Polymyositis Market Trends and Forecasts with DelveInsight @ Polymyositis Treatment Market- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Polymyositis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Polymyositis Companies- Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
• Polymyositis Therapies- Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.
• Polymyositis Therapeutic Assessment: Polymyositis Current marketed and Polymyositis Emerging Therapies
• Polymyositis Market Dynamics: Polymyositis Market drivers and Polymyositis Market Barriers

Unlock Strategic Insights with DelveInsight's Comprehensive Polymyositis Market Report @ Polymyositis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Polymyositis Market Report Introduction
3 Polymyositis Market Overview at a Glance
4 Polymyositis Epidemiology and Market Forecast Methodology
5 Polymyositis Key Events
6 Polymyositis Executive Summary
7 Polymyositis Disease Background and Overview
8 Polymyositis Epidemiology and Patient Population
9 Polymyositis Patient Journey
10 Polymyositis Emerging Therapies
11 Polymyositis: Seven Major Market Analysis
12 Polymyositis KOL Views
13 Polymyositis SWOT Analysis
14 Polymyositis Unmet Needs
15 Polymyositis Market Access and Reimbursement
16 Polymyositis Appendix
17 Polymyositis Market Report Methodology
18 DelveInsight Capabilities
19 Disclaimer
18 Bibliography
19 DelveInsight Capabilities
20 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.